Viyash Scientific Posts Q1 FY27 Results Amidst Strategic Expansion

Revenue from operations stood at ₹946.36 crore, with Profit After Tax at ₹79.29 crore for the quarter ended June 30, 2026.

Reader Takeaway: Growth via expansion and market entry, but hyperinflationary risks and restated financials need monitoring.

What just happened

Viyash Scientific Limited announced its financial results for the first quarter of FY27, reporting revenue of ₹946.36 crore and a profit after tax of ₹79.29 crore. The company also approved several strategic moves, including a rights issue of up to ₹400.02 crore for its subsidiary Alivira Animal Health Limited, the incorporation of Alivira Vietnam Company Limited, and the acquisition of 100% stake in Italy-based BioForlife Italia S.r.l.

Why this matters

These developments signal Viyash Scientific's focus on expanding its global footprint in the animal health sector and optimizing its subsidiary's financial structure. The rights issue aims to strengthen Alivira Animal Health's capital base and reduce its interest costs. The acquisition in Italy further diversifies the group's geographical presence and product portfolio.

The backstory

This update follows a period of restructuring, with prior-year financials restated due to a Composite Scheme of Amalgamation. The company's operations in Turkey are subject to hyperinflationary accounting standards (Ind AS 29), which can impact financial reporting volatility.

What changes now

The approved strategic initiatives are expected to drive future growth. The company will now proceed with the incorporation of its Vietnam subsidiary, the rights issue in Alivira Animal Health, and the integration of BioForlife Italia into its operations. The allotment of 1,030,775 shares under ESOP Scheme 2026 also increases the company's equity base.

Risks to watch

Operating in a hyperinflationary economy like Turkey poses a significant risk due to potential volatility in financial results. Investors must also consider the complexities arising from restated financial comparatives due to past amalgamations.

Peer comparison

While specific peer financial data for Q1 FY27 is not yet available, Viyash Scientific operates in the animal health and pharmaceutical ingredients space, competing with other established players in India and international markets.

Context metrics (time-bound)

For the quarter ended June 30, 2026:

• Revenue from operations: ₹946.36 crore
• Profit after tax: ₹79.29 crore
• Basic EPS: ₹1.51
• Rights issue for Alivira Animal Health: Up to ₹400.02 crore
• Acquisition of BioForlife Italia: EURO 16.976 million

What to track next

Investors should monitor the progress of the Vietnam subsidiary's setup, the successful completion of the rights issue and its impact on AAHL's debt, and the integration of the Italian acquisition. Performance in hyperinflationary markets will also be a key area to watch.